Articles by George Koroneos, Online Content & News Editor - Pharmaceutical Executive


Articles by George Koroneos, Online Content & News Editor

Drug Sales See Minimal Climb in 2008

Mar 25, 2009

Farewell to double-digit growth. Between patent expirations and a sagging economy, sales of prescription drugs grew only 1.3 percent last year.

Fixing Pfizer's Rep

Mar 18, 2009

Pharm Exec sits down with Kathryn Metcalfe, Pfizer's new vice president of corporate reputation and policy communications to discuss the new position, the perception of pharma among laypeople, and what needs to be done to boost public opinion of the drug industry.

Pharma Media Spend Falls 18.4 Percent

Mar 18, 2009

With the economy in turmoil, pharmaceutical manufacturers are reassessing where and how they spend their advertising dollars.

Roche and Genentech Seal the Deal for $46.8 Billion

Mar 5, 2009

After months and months of back and forth over the true value of Genentech, Roche finally got the good news it's been looking for: Genentech's board of directors, this morning, approved Roche's latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant.

Merck Takes Unusual Merger Tactic in Schering Deal

Mar 4, 2009

The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep Schering's licensing deals secure. Was it the right move?

Wyeth Loses Preemption Battle

Mar 4, 2009

The Supreme Court ruled in favor of the plaintiff in a case that has had the pharmaceutical industry on pins and needles. The verdict hammered home the fact that even though FDA approves a drug, pharmaceutical companies are responsible for making labels as clear as possible.

GSK Garners FDA Warning Letter for Extraterrestrial Ad Campaign

Mar 4, 2009

GlaxoSmithKline received a warning letter for use of misleading imagery in its television ad for Avodart. The Feds felt that comparing prostate size to planets might not be a good idea.

Pfizer Pulls Two Late-stage Drugs from Development

Feb 25, 2009

A sign of the times or a rash decision? In an effort to curb unnecessary costs, Pfizer kills development of two late-stage products rather than sink more money into them.

Specialty Firms Shoot Down Big Money Bids

Feb 25, 2009

CV Therapeutics and Genetech rejected offers from big-name suitors. Are they playing hard to get or are they just not that into them?


Click here